A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Non-Pustular PalmoPlantar and Genital Psoriasis (Psoriatyk Special Sites)
Latest Information Update: 25 Jul 2025
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Palmoplantar pustulosis; Plaque psoriasis; Psoriasis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 14 May 2025 Status changed from active, no longer recruiting to discontinued.
- 13 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 04 Mar 2025 Planned End Date changed from 28 Oct 2026 to 27 Oct 2026.